Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Permissive Hyperthermia in Acute Brain Injury

NCT07709325 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2026-04-25
Last updated
2026-07-16

Condition(s) studied

Fever

Investigational drug(s) / intervention(s)

Temperature < 39,5Temperature <37.5

Temperature < 39,5: Allowing temperature up to 39,5 in patients with acute brain injury

Temperature <37.5: Standard care of temperature

Study summary

The purpose of this pilot study is to find out whether it is possible to work together with the body's own reactions, where the temperature goes up (fever), in a safe and controlled way.

The main question to answer is:

Is it practical and safe to allow higher body temperature (up to 39.5°C) as part of the treatment for critically ill patients with brain injury?

Patients with acute brain injury will be Placed in one of two groups: one where fever is treated to keep the temperature below 37.5°C, and one where fever is allowed up to 39.5°C.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Severe acute brain injury. * Requirement for: Mechanical ventilation Sedation Intracranial pressure (ICP) monitoring Exclusion Criteria: * Pregnancy * Moribund patients or patients in whom withdrawal of active treatment is anticipated

Primary outcome measure(s)

  • Record numbers of episodes and the time frame when temperature needed to be lowered to maintain acceptable intracranial pressure. — 14 days from enrollment, or until multi-bolt has been removed, or the patients had died
    This only applies to patients included in the group, where temperatures up to 39.5°C are allowed

Trial sites (1)

FacilityCityRegionStatus
Neurointensiv care Odense C Denmark
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07709325 on ClinicalTrials.gov ↗ ← All trials in Denmark